Filter:
Industry:

Active

Select exits

Cases

 
H

HOBA Therapeutics

Innovative biopharmaceuticals for patients with neuropathic pain

Unique Value Proposition

Development of the neurotrophic growth factors HB-086 and HB-097. The molecules constitute a unique family significantly differentiated from currently know neuronal growth factors. They both support neuroprotective and neuroregenerative functions and can improve quality of life for patients suffering from neuropathic pain and central nervous system disorders.

Business Model

Development and sale of products.

Stage

Proof of Technology

 


HOBA Therapeutics
Ole Maaløes Vej 3, 2200 2200
3110 1285 · keap@hobatherapeutics.com
www.hobatherapeutics.com

CEO: Kenneth A. Petersen

C

Contact

Thor Jespersen, CEO
+45 9635 4520 ·
Aalborg

Thor manages Borean Innovation. He has the executive responsibility for our investments and the portfolio of companies we have invested in.

Thor has his own experience as CEO of a venture-financed company. Moreover, Thor has extensive experience working with general management, commercial law, venture investments and M&A, both within the industrial sector and the venture capital industry. 

Educational background 

M.Sc. in Business Administration and Commercial Law
Management education from CEDEP and INSEAD

Portfolio